- Home
- FND vs MIRM Comparison
FND vs MIRM Comparison
Compare FND & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FND | MIRM |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.7B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FND | MIRM |
|---|---|---|
| Price | $47.73 | $106.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $73.44 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 2.9M | 667.9K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.05 | ★ 74.59 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,684,088,000.00 | $19,138,000.00 |
| Revenue This Year | $7.53 | $26.22 |
| Revenue Next Year | $7.68 | $22.04 |
| P/E Ratio | $131.76 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $46.47 | $42.89 |
| 52 Week High | $92.41 | $112.00 |
Technical Indicators
Market Signals| Indicator | FND | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 62.25 |
| Support Level | $46.50 | $87.26 |
| Resistance Level | $55.38 | $107.51 |
| Average True Range (ATR) | 2.46 | 5.87 |
| MACD | 0.11 | 0.98 |
| Stochastic Oscillator | 18.02 | 75.13 |
Price Performance
Historical ComparisonAbout FND Floor & Decor Holdings Inc.
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.